• Phare
  • Validé par KD/KO

Anticorps Polyclonal de lapin anti-PD-L1/CD274

PD-L1/CD274 Polyclonal Antibody for WB, IP, IF, IHC, ELISA

Hôte / Isotype

Lapin / IgG

Réactivité testée

Humain, rat, souris

Applications

WB, IHC, IF/ICC, IP, CoIP, ChIP, ELISA, Cell treatment

Conjugaison

Non conjugué

N° de cat : 17952-1-AP

Synonymes

CD274, PD-L1, B7 H1, B7-H1, hPD-L1, PD L1, PDCD1 ligand 1, PDCD1L1, PDCD1LG1, PDL1



Applications testées

Résultats positifs en WBtissu placentaire humain, cellules A375, cellules A549 traitées par IFN gamma, cellules HeLa, cellules HepG2, cellules K-562, tissu cardiaque de souris, tissu cardiaque humain, tissu de muscle squelettique de souris
Résultats positifs en IPtissu cardiaque de souris
Résultats positifs en IHCtissu d'amygdalite humain, tissu cardiaque de souris, tissu de cancer de l'estomac humain
il est suggéré de démasquer l'antigène avec un tampon de TE buffer pH 9.0; (*) À défaut, 'le démasquage de l'antigène peut être 'effectué avec un tampon citrate pH 6,0.
Résultats positifs en IF/ICCcellules HEK-293

Dilution recommandée

ApplicationDilution
Western Blot (WB)WB : 1:500-1:1000
Immunoprécipitation (IP)IP : 0.5-4.0 ug for 1.0-3.0 mg of total protein lysate
Immunohistochimie (IHC)IHC : 1:300-1:1200
Immunofluorescence (IF)/ICCIF/ICC : 1:10-1:100
It is recommended that this reagent should be titrated in each testing system to obtain optimal results.
Sample-dependent, check data in validation data gallery

Informations sur le produit

17952-1-AP cible PD-L1/CD274 dans les applications de WB, IHC, IF/ICC, IP, CoIP, ChIP, ELISA, Cell treatment et montre une réactivité avec des échantillons Humain, rat, souris

Réactivité Humain, rat, souris
Réactivité citéerat, Humain, souris
Hôte / Isotype Lapin / IgG
Clonalité Polyclonal
Type Anticorps
Immunogène PD-L1/CD274 Protéine recombinante Ag12432
Nom complet CD274 molecule
Masse moléculaire calculée 290 aa, 33 kDa
Poids moléculaire observé 45-56 kDa, 65-70 kDa
Numéro d’acquisition GenBankBC074984
Symbole du gène PD-L1
Identification du gène (NCBI) 29126
Conjugaison Non conjugué
Forme Liquide
Méthode de purification Purification par affinité contre l'antigène
Tampon de stockage PBS avec azoture de sodium à 0,02 % et glycérol à 50 % pH 7,3
Conditions de stockageStocker à -20°C. Stable pendant un an après l'expédition. L'aliquotage n'est pas nécessaire pour le stockage à -20oC Les 20ul contiennent 0,1% de BSA.

Informations générales

PD-L1, also known as CD274 or B7H1, stands for programmed cell death ligand 1. It is a type I transmembrane protein that is thought to repress immune responses by binding to its receptor (PD1), thus inhibiting T-cell activation, proliferation, and cytokine production. It contains V-like and C-like immunoglobulin domains. PD-L1 expression is regulated by various cytokines, such as TNF-α or LPS (ISSN: 1848-7718). Increased expression of this protein in certain types of cancers, e.g., renal cell carcinoma or colon cancer, correlates with poor prognosis. 

What is the molecular weight of PD-L1? 

Depending on the isoform, the calculated molecular weight of the protein varies between 20 and 33 kDa (176-290 aa). 

What are the isoforms of PD-L1? 

According to NCBI, three different isoforms have been identified. There are significant differences in the untranslated and protein coding regions. 

What is the subcellular localization and tissue specificity of PD-L1? 

It is predicted to localize in the plasma membrane of various cell types, with a particularly high expression in placental trophoblast and subsets of immune cells. High levels of PD-L1 protein have also been detected in lung and colon tissues. 

What is the function of PD-L1 in immune responses? 

PD-L1 is critical for the induction and maintenance of immune self-tolerance during infection or inflammation in normal tissues. The interaction of PD-L1 and its receptors is responsible for preventing auto-immune phenotypes and balancing the overall immune response in situations such as pregnancy or tissue allografts. The interaction between PD-L1 and PD-1 or B7.1 starts an inhibitory signaling cascade, which results in the decreased proliferation of antigen-specific T-cells and increased survival of regulatory T-cells (PMID: 15240681). 

How can PD-L1's implication in cancer be used as a drug target? 

In certain tumors, high expression of PD-L1 serves as a stop-sign to inhibit the recognition of cancer cells by T-cells (PMID: 23087408). The interaction between PD-L1 and its receptors (PD1 and B7.1) is a mechanism for the tumor to evade the host immune response (PMID: 29357948). Several mAbs have been developed to target that interaction and thus prevent the inactivation of cytotoxic T-cells by the tumor (PMIDs: 23890059, 18173375).


Protocole

Product Specific Protocols
WB protocol for PD-L1/CD274 antibody 17952-1-APDownload protocol
IHC protocol for PD-L1/CD274 antibody 17952-1-APDownload protocol
IF protocol for PD-L1/CD274 antibody 17952-1-APDownload protocol
IP protocol for PD-L1/CD274 antibody 17952-1-APDownload protocol
Standard Protocols
Click here to view our Standard Protocols

Publications

SpeciesApplicationTitle
humanWB

Nat Biomed Eng

Inhibiting PD-L1 palmitoylation enhances T-cell immune responses against tumours.

Authors - Han Yao
humanIHC

Nat Commun

Pharmaceutical targeting of OTUB2 sensitizes tumors to cytotoxic T cells via degradation of PD-L1

Authors - Wenfeng Ren
humanWB

Adv Sci (Weinh)

BiTE-Secreting CAR-γδT as a Dual Targeting Strategy for the Treatment of Solid Tumors

Authors - Shi-Wei Huang
human,mouseIHC,IF

Acta Pharm Sin B

Whole-body PET tracking of a d-dodecapeptide and its radiotheranostic potential for PD-L1 overexpressing tumors.

Authors - Kuan Hu
humanWB,IHC,IF

Mol Cell

Phosphorylated RB Promotes Cancer Immunity by Inhibiting NF-κB Activation and PD-L1 Expression.

Authors - Xin Jin
humanWB,IHC,IF

Mol Ther

Targeting leucine-rich repeat serine/threonine-protein kinase 2 sensitizes pancreatic ductal adenocarcinoma to anti-PD-L1 immunotherapy

Authors - Kang Sun